Controlling Hypertension in Primary Care: Hitting a moving target?
|
|
- Quentin Rodgers
- 5 years ago
- Views:
Transcription
1 Controlling Hypertension in Primary Care: Hitting a moving target? David J. Hyman, MD,MPH Professor of Medicine and Family & Community Medicine Chief, Section General Medicine Baylor College of Medicine No Conflicts of Interest
2 Controlling Hypertension in Primary Care: Hitting a moving target? Objectives Review why hypertension is the most important topic in medicine and the great job that primary care is doing Be familiar with the shifting and conflicting guidelines: JNC 7, JNC 8 now AHA/ACC 2017 vs AAFP/ACP 2017 vs. other international groups vs NCQA (clinical quality) metrics Appreciate the critical role of how the blood pressure is measured in interpreting the guidelines Be relieved by the lack of controversy in drug regimens Recognize and intervene on resistant hypertension
3 Hypertension is the most important topic in medicine.
4 Prevalence of Hypertension in the United States* 100% Hypertension Prevalence 80% 60% 40% 20% 6% 16% 31% 48% 65% 78% 0% Age *Based on NHANES data. Hypertension is defined as blood pressure 140/90 mmhg or antihypertensive treatment. Low reliability due to large relative error. Fields et al. Hypertension. 2004:44;
5 Benefits of Lowering BP Average Percent Reduction Stroke incidence 35 40% Myocardial infarction 20 25% Heart failure 50%
6 Global Disability Adjusted Life Years (DAYLs) Attributable to the 25 Leading Risk Factors 2010 Risk Factor 2010 Rank DALYs (95% UI) in thousands High blood pressure 1 173,556 ( Tobacco smoking, including exposure to secondhand smoke 2 156,838 (136, ) Household air pollution from solid fuels 3 108,084 (84, ,983) Diet low in fruit 4 104,095 (81, ,169) Alcohol use 5 97,237 (87, ) High body-mass index 6 93,609 (77, ,600) High fasting plasma glucose level 7 89,012 (77, ,390) Childhood underweight 8 77,316 (64,497-91,943) Expo sure to amblent particulate-matter pollution 9 76,163 (68,086-85,171) Physical inactivity or low level of activity 10 69,318 (58,646-80,182) Murray, Christopher J, et. al, New England Journal of Medicine, 2013
7 Diabetes: Tight Glucose vs Tight BP Control and CV Outcomes in UKPDS % Reduction In Relative Risk Stroke 5% 44% * Any Diabetic Endpoint 12% 24% * DM Deaths 10% Tight Glucose Control (Goal <6.0 mmol/l or 108 mg/dl) 32% Microvascular Complications 32% *P <0.05 compared to tight glucose control * 37% * Tight BP Control (Average 144/82 mmhg) Bakris GL, et al. Am J Kidney Dis. 2000;36(3): Reprinted by permission, Harcourt Inc.
8 Hypertension Control Horrible-Isn t it? Less than ½ of persons with hypertension are controlled 70% of people who start BP drugs stop within 5 years..
9 Blood Pressure Control Over Time Chobanian, N Engl J Med 2009;361:
10 The percentages are shown (mean and 95% confidence intervals) for hypertension prevalence, awareness, treatment, control, and proportion of treated patients controlled (control/treated) among adults 18 years of age in NHANES 1999 to 2012 at 2-year increments. Egan B M et al. Circulation. 2014;130: Copyright American Heart Association, Inc. All rights reserved.
11 Another database showing Hypertensives are mostly adherent 625,000 patients with prescription refill records available from insurer Adherent (>80%) 74.6% Moderate (60-79%) 15.3% Poor (<60%) 9.9% Pittman DG, et al Am J Managed Care 2010
12 Harris Health October 2018
13 Controlling Hypertension in Primary Care: Hitting a moving target? - Be familiar with the shifting and conflicting guidelines: JNC 7, JNC 8 now AHA/ACC 2017 vs AAFP/ACP 2017 vs. other international groups vs NCQA (clinical quality) metrics
14
15 Hypertension Treatment Effect Mirrors Observational Data Incidence of cardiovascular disease Systolic blood pressure (mmhg)
16 National Heart, Lung, and Blood Institute National High Blood Pressure Education Program U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)
17 JNC BP Classifications: DBP Stage 4 DBP (mm Hg) Hypertensive Consider therapy Severe Severe Severe Moderate Moderate Moderate Mild Mild Mild Stage 3 Stage 3 Stage 2 Stage 2 Stage 1 Stage 1 Stage 2 Stage Normal Normal Normal Normal Optimal Optimal Highnormal Highnormal Highnormal Highnormal Prehypertension Normal JNC I JNC II JNC III JNC IV JNC V JNC VI JNC 7 JNC I. JAMA. 1977;237: JNC II. Arch Intern Med. 1980;140: JNC III. Arch Intern Med. 1984;144: JNC IV. Arch Intern Med. 1988;148: JNC V. Arch Intern Med. 1993;153: JNC VI. Arch Intern Med. 1997;157: Chobanian AV et al. JAMA. 2003;289:
18 Hypertension. 1999;34:
19 JNC BP Classifications: SBP SBP (mm Hg) No recommendations for SBP in JNC I or JNC II ISH Border - line ISH Border - line Normal Stage 2 Stage 1 Stage 4 Stage 3 Stage 3 Stage 2 Stage 2 Stage 1 Stage 1 Highnormal Highnormal Normal Normal Optimal Optimal Prehypertension Normal JNC I JNC II JNC III JNC IV JNC V JNC VI JNC 7 JNC I. JAMA. 1977;237: JNC II. Arch Intern Med. 1980;140: JNC III. Arch Intern Med. 1984;144: JNC IV. Arch Intern Med. 1988;148: JNC V. Arch Intern Med. 1993;153: JNC VI. Arch Intern Med. 1997;157: Chobanian AV et al. JAMA. 2003;289:
20 Goals of Therapy JNC 8 majority report: over age 60: DM, cad, Ckd 150/90 mm/hg 140/90 mm/hg JNC 8 minority report: over age 60: 140/90 mm/hg
21 2010 Accord BP Diabetics 120mmHg vs. 140mmHg Negative 2013 SPS3 Post subcortical <130 mmhg vs < 140 mmhg Negative stroke 2015 SPRINT high risk 120mmHG vs. 140mmHG Stopped early!! not DM or CVA Benefit
22 Sprint Trial Major inclusion criteria Age > 50 SBP (tx or un tx) At least one of : Clinical CVD except CVA CKD egfr Framingham 10yr CVD risk > 15% Age >75 Major exclusion criteria Stroke DM CHF(sx or EF<35%) proteinuria >1 g/d CKD egfr <20 ADHERENCE CONCERNS SBP achieved: mmhg NNT event 61 NNT to Prevent one death 90
23 AHA/ACC 2017 vs everyone else
24 AHA 2017
25 Changes in BP Categories from JNC 7 to the 2017 ACC/AHA HTN Guideline SBP DBP JNC ACC/AHA <120 and <80 Normal BP Normal BP and <80 Prehypertension Elevated BP or Prehypertension Stage 1 hypertension or Stage 1 hypertension Stage 2 hypertension 160 or 100 Stage 2 hypertension Stage 2 hypertension The 2017 ACC/AHA guideline definition of hypertension: SBP 130 mm Hg or DBP 80 mm Hg
26
27
28
29 If same patient was 60WF 10 yr risk 4.8% If 40 WM 10 yr risk 1.8% If 40 BM 10 yr risk 10.0% If 60 WM,BM,BF 10 yr risk >10% You have to use the calculator, guesstimates difficult
30 Prevalence of Hypertension 2017 ACC/AHA and JNC 7 Guidelines Prevalence of hypertension, % Number of US adults with hypertension, millions 13.7% 31.1, M Muntner et. al., Journal of the American College of Cardiology 2017, Nov 6 Muntner, et. al., Circulation 2017 Nov 13
31 JNC 8 AHA/ACC 2017 ESC/ESH 2018 ACP/AAFP 2017 Threshold for starting by age >60 150/90 < /90 all ages 140/90 130/80 High risk < /90 >80 160/90 >60 150/no rec strong >60 CVA/TIA consider 140 (weak) >60 high risk consider 140 (weak Target for on treatment BP >60 150/90 <60 140/90 <130/ to 130 but not <120 > >60 < 150 >60 CVA/TIA consider 140mmHG (weak) >60 High risk consider 140 mmhg (weak)
32 Hitting the target How do you measure the BP you are acting on?
33 BP Measurement Techniques Method In-office Brief Description Two readings, 5 minutes apart, sitting in chair. Confirm elevated reading in contralateral arm. Ambulatory BP monitoring Indicated for evaluation of white-coat HTN. Absence of 10 20% BP decrease during sleep may indicate increased CVD risk. Self-measurement In Office automated unobserved May help improve adherence to therapy and evaluate white-coat HTN. Pt alone in room
34 If mean office visit SBP 140mmHG control about 50% frequency 68% 95% 99.7% mean Number of standard deviations either side of mean
35 AHA 2017
36 Sprint Maybe much ado about nothing? 1) Sprint used unobserved Automated Office BP (AOBP) - pt seated alone in room for 5 minutes - only after 5 minutes of rest, would take 3 measurement 1 minute apart unobserved AOBP averages SBP 16mmHG lower than regular office BP often similar to day ABPM 2) Intervention achieved SBP mmhg = about current 140 3) Control group had target of 140mmHG, could have baseline medications reduced to get there actual SBP controls mmhg = if individual at 140, = 166 Kjeldsen & Mancia European Heart J 2016
37 What BPs are we being graded on?
38 Definition of Hypertension Control in Clinical Practice NCQA/ HEDIS Enrolled for 1 year or more Have a hypertension code in 1st 6 months of year Age BP at last visit in chart used Control: < 140 and < 90 mmhg at sampled visit Sennett C, Managed Care 2000
39 NCQA HEDIS 2019 < 140/90 on last visit in evaluation period or remote BP devices electronically submitted HEDIS / w dm 140/ w/o dm 150/90
40 BP Drugs now the easy part - It will likely take more than one drug, tell patients this right from start - If it is really high start 2 drugs - Multidrug combination pills maybe good - If the blood pressure is high on subsequent visits- titrate the medication!!!! Clinical Inertia: not lack of access or non-adherence is biggest reason for lack of control
41 Order of BP medication use: 1 st (Ace or ARB) or CCB or Diuretic For DM (Ace or ARB ) For African Origin no DM: CCB or Diuretic 2 nd (Ace or ARB) and CCB or (ACE or ARB) and Diuretic 3 rd (Ace or ARB) and CCB and Diuretic 4 th spironolactone Only then, the other classes Sometimes other classes needed for other conditions or contraindications
42 NO ENALAPRIL Use Lisinopril Few B blockers NO Atenolol The REAL Dose of HCTZ is 50mg Chlorthalidone may be coming to Harris Health
43
44 What if the patient s Blood Pressure does not respond? RESISTANT HYPERTENSION
45 Definitions Resistant Hypertension: office blood pressure that remains elevated despite optimal doses of 3 classes of medication including diuretic if tolerated or controlled on 4 medicines Pseudo-resistant Hypertension: seems to meet definition but on further evaluation pt is -Non-adherent - Controlled on 24 hour ABPM - not really on optimal medications, - only uncontrolled on poor office measurement True resistant: not pseudo- resistant Apparent Resistant Hypertension: seems to meet definition but pseudo-resistant not ruled out
46 Apparent Resistant Hypertension Drilling down on the medical regimen: Source Result Persell NHANES Any diuretic 86% 2011 Study BP, drug names loop 30% not dosage thiazide like 59%(HCTZ 93%) 539 patients uncontrolled > 3 aldo antagonists 3.0% or controlled > 4 drugs Hanselin Drug insurance data base Any diuretic 93% 2011 drug names, dose, No BPs loop 19% 140,000/5million hypertensives on thiazide like 80% (HCTZ 94%) > 4 drugs Chlorthalidone 3%, aldo antagonist 5.9% HCTZ mean dose 21.1 mg Fontil National Ambulatory Medical Care Survey Any diuretic 77% drug names, no dosages, office BP loop 23 % 1567 pts w uncontrolled > 3 or controlled thiazide like 56% (HCTZ 96%) > 4 drugs Chlorthalidone 1.2% aldo antagonists 3.9% Grigoryan Primary care patients uncontrolled Any Diuretic 91% 2013 > 3 drugs, n=34 loop 15% Drug names, doses, ABPM, thiazide like 84% (HCTZ electronic adherence monitor Chlorthalidone 0% aldo antagonists 0% > ½ max dose ace/arb/ccb HCTZ 24/26 at 25mg QD
47 Resistant Hypertension Uncommon if Appropriate Drugs used In a network of 200 practices across the Southeast with 468,000 treated hypertensives those uncontrolled on 3 or more drugs at acceptable dose: 4.7% Egan B, Zhao Y, Li J et al
48 Houston TX On a very detailed drill down using ABPM and electronic bottle cap monitoring: of Apparent resistant hypertenvsives (N=69) 22% normal ABPM 29% non adherent Essentially no one optimally treated, mostly HCTZ 25,no Chlorthalidone, no spironolactone Grigoryan L, Pavlik VN, Hyman DJ J Am Soc Hypertens 2013
49 Patients with severe BP elevations referred to resistant hypertension clinics or for device therapy have very high levels of non-adherence when measured by blood or urine samples
50 Diuretics are the key to controlling difficult to control hypertension The dose of HCTZ is 50mg!!!!!! Chlorthalidone if you can get it- 25 mg Spironolactone 25 to 50 mg is 4 th drug Eplerenone is alternative
51 What is real prevalence of resistant hypertension? A network of 200 practices across the Southeast 468,000 treated hypertensives - uncontrolled on 3 or more drugs at acceptable dose Semi Apparent Resistant Hypertension 4.7% Egan B, Zhao Y, Li J et al
52 Diuretics are the key to controlling difficult to control hypertension The dose of HCTZ is 50mg!!!!!! Chlorthalidone if you can get it- 25 mg Spironolactone 25 to 50 mg is 4 th drug Eplerenone is alternative
53 Conclusions Hypertension is the most important topic in Medicine! You don t have to accept the 2017 AHA/ACC guideline A well measured in office 140/90 is good criteria for starting 130/80 maybe indicated is some high risk patients 130/80 maybe reasonable target if well tolerated It is very fair that we will still be graded on 140/90 If someone actually fits SPRINT criteria, and wants to do it- go for it! but remember it is an average SBP 121mm, not always less than 120mmHG
54 Conclusions continued.. Measurement counts- follow the literature -follow your office practicethe closer to Automated Office BP method the better Do drugs! ACE(ARB) CCB diuretics Hctz 50 aldactone 4 th Resistant hypertension: check adherence. Rare referral for 2 nd hypertension
55 Hypertension is the most important topic in medicine!!! Please do not let any differences in guidelines lead us to nihilism and inaction!!!
56
Management of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationHYPERTENSION: ARE WE GOING TOO LOW?
HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More information2/11/2019 CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES DUALITY OF INTEREST
CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES George L. Bakris, M.D.,F.A.S.N., F.A.H.A. Professor of Medicine Director, Am Heart Assoc. Comprehensive Hypertension Center University of Chicago Medicine
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationHypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA
Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationNone. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationObjectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence
JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician
More informationHypertension: 2016 Clinical Update
PHASE Safety Net Community Benefit Hypertension: 2016 Clinical Update Presented by: Joseph Young, MD Hypertension Clinical Lead Kaiser Permanente Northern California October 6, 2016 Dr. Joseph Young Hypertension
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationHYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More informationPHASE Preventing Heart Attacks & Strokes Everyday
PHASE Preventing Heart Attacks & Strokes Everyday Welcome to the PHASE Learning Community! Joseph D. Young, MD Kaiser Permanente Northern California Jean Nudelman Kaiser Permanente Northern California
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationChallenges in Hypertension: Incorporating Evolving Clinical Data Into Practice
Challenges in Hypertension: Incorporating Evolving Clinical Data Into Practice Faculty Jan Basile, MD Professor of Medicine Seinsheimer Cardiovascular Health Program Division of General Internal Medicine
More informationManaging Hypertension in 2018
MANAGING HYPERTENSION IN 2018 How Do We Work With Conflicting Data and Conflicting Guidelines? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School
More informationRESISTANT HYPERTENSION
RESISTANT HYPERTENSION John D. Bisognano, MD PhD Professor of Medicine / Cardiology President-Elect, American Society of Hypertension Director, Outpatient Cardiology University of Rochester RESISTANT HYPERTENSION
More informationHypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington
Hypertension Guidelines: Lessons for Primary Care Paul A James MD Professor and Chair Department of Family Medicine University of Washington Disclaimer and Financial Disclosure I have no financial interests
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationEvaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016
Evaluation and Management of Hypertension in Women Vesna D. Garovic, M.D. Moscow, Russia, December 2016 2016 MFMER 3508058-1 Women are not small men There is nothing as powerful as an idea whose time has
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationΣτόχοι αρτηριακής πίεσης σε ειδικούς πληθυσµούς και επιλογή φαρµάκων
Στόχοι αρτηριακής πίεσης σε ειδικούς πληθυσµούς και επιλογή φαρµάκων Εύα Καρπάνου Δ/ντρια Αντιυπερτασικού Ιατρείου Α ΚΚ Ωνάσειου ΚΚ Θεσσαλονίκη, 14/2/13 Η µελέτη δεν υποστηρίχθηκε από φαρµακευτικές εταιρείες
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationBest Practices in Cardiac Care: Getting with the Guidelines
Best Practices in Cardiac Care: Getting with the Guidelines December 9, 2014 Agenda Cardiovascular Disease: How do the guidelines fit into an implementation scheme? What the guidelines set out to accomplish
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationHypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations
Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationOsama Sanad (MD) Prof. of Cardiology Benha University 2016
Osama Sanad (MD) Prof. of Cardiology Benha University 2016 Back in time. 1912 Back in time. 1912 No body knows that hypertension is a lethal disease Hypertension in 1940s Among anti-hypertensives mentioned
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationRenal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School
Renal Denervation by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School Disclosure Information ACOI Annual Meeting I have the following financial relationships to disclose:
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationBrent M. Egan, MD Professor of Medicine USCSOM Greenville
Contemporary Management of Uncontrolled and Treatment Resistant Hypertension Brent M. Egan, MD Professor of Medicine USCSOM Greenville Disclosures (past 3 years): Honoraria: BCBSSC, Medtronic Grant Support:
More informationJNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines
JNC-8 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines Derrick Sorweide, DO Assistant Professor of Family Medicine,
More informationMasked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre
Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:
More informationHypertension: Update
Hypertension: Update Meenakshi A Bhalla MD,FACC Associate Professor of Medicine Director Preventive Cardiology Advanced Heart Failure and Transplant Cardiology University of Kentucky Faculty Disclosure
More informationHypertension Guidelines 2017
Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationHypertension Controversies: SPRINTing to New Goals
Hypertension Controversies: SPRINTing to New Goals Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Lauren Wolfe, PharmD Primary Care Clinical Specialist Cleveland
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationManagement of Hypertension in Women
Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been
More information2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.
Achieving Harmony in Blood Pressure Guidelines Around the Globe Roger S. Blumenthal, MD The Kenneth Jay Pollin Professor of Cardiology Director, The Johns Hopkins Ciccarone Center for the Prevention Of
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationManagement of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB
Management of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB Increasing stroke numbers in New Zealand an 'epidemic' says leading AUT
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationHypertension Update. Aaron J. Friedberg, MD
Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:
More informationManagement of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationEvolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)
Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationHypertension Update. Faculty/Presenter Disclosure
Hypertension Update Who Gives a CHEP About Targets? Faculty/Presenter Disclosure Presenter: Raj Padwal Relationships that may introduce potential bias and/or conflict of interest: Grants/Research Support:
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationBlood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
More informationHypertension Guidelines Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center
Hypertension Guidelines 2016 Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center Speaker Disclosures I disclose that I am a Consultant for: Ablative
More informationUpdates in Cardiovascular Recommendations for Diabetic Patients
Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More information